

- [46] Nataro JP, Barry EM. Diarrheal disease vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. *Vaccines* 5th ed: Saunders-Elsevier, 2008: 1163-71.
- [73] Peltola H, Siitonen A, Kyronseppa H, Simula I, Mattila L, Oksanen P, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. *Lancet* 1991;338:1285-9.
- [74] Lopez-Gigosos R, Garcia-Fortea P, Reina-Dona E, Plaza-Martin E. Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS. *Travel Med Infect Dis* 2007;5:380-4.
- [95] Karmali MA. Infection by Shiga toxin-producing *Escherichia coli*: an overview. *Mol Biotechnol* 2004;26:117-22.
- [96] Konadu EY, Parke JC, Jr., Tran HT, Bryla DA, Robbins JB, Szu SC. Investigational vaccine for *Escherichia coli* O157: phase 1 study of O157 O-specific polysaccharide-*Pseudomonas aeruginosa* recombinant exoprotein A conjugates in adults. *J Infect Dis* 1998;177:383-7.
- [97] Qadri F, Svennerholm AM, Faruque AS, Sack RB. Enterotoxigenic *Escherichia coli* in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. *Clin Microbiol Rev* 2005;18:465-83.
- [98] Black RE. Epidemiology of diarrhoeal disease: implications for control by vaccines. *Vaccine* 1993;11:100-6.
- [99] Wenneras C, Erling V. Prevalence of enterotoxigenic *Escherichia coli*-associated diarrhoea and carrier state in the developing world. *J Health Popul Nutr* 2004;22:370-82.
- [100] Steffen R, Castelli F, Dieter Nothdurft H, Rombo L, Jane Zuckerman N. Vaccination against enterotoxigenic *Escherichia coli*, a cause of travelers' diarrhea. *J Travel Med* 2005;12:102-7.
- [101] Niyogi SK. Shigellosis. *J Microbiol* 2005;43:133-43.
- [102] Rao MR, Abu-Elyazeed R, Savarino SJ, Naficy AB, Wierzba TF, Abdel-Messih I, et al. High disease burden of diarrhea due to enterotoxigenic *Escherichia coli* among rural Egyptian infants and young children. *J Clin Microbiol* 2003;41:4862-4.
- [103] Qadri F, Saha A, Ahmed T, Al Tarique A, Begum YA, Svennerholm AM. Disease burden due to enterotoxigenic *Escherichia coli* in the first 2 years of life in an urban community in Bangladesh. *Infect Immun* 2007;75:3961-8.
- [104] Begum YA, Talukder KA, Nair GB, Khan SI, Svennerholm AM, Sack RB, et al. Comparison of enterotoxigenic *Escherichia coli* isolated from surface water and diarrhoeal stool samples in Bangladesh. *Can J Microbiol* 2007;53:19-26.
- [105] Black RE. Epidemiology of travelers' diarrhea and relative importance of various pathogens. *Rev Infect Dis* 1990;12 Suppl 1:S73-9.
- [106] Al-Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. *Lancet Infect Dis* 2005;5:349-60.
- [107] Flores J, DuPont HL, Lee SA, Belkind-Gerson J, Paredes M, Mohamed JA, et al. Influence of host interleukin-10 polymorphisms on development of traveler's diarrhea due to heat-labile enterotoxin-producing *Escherichia coli* in travelers from the United States who are visiting Mexico. *Clin Vaccine Immunol* 2008;15:1194-8.
- [108] Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. *Curr Top Microbiol Immunol* 1999;236:215-36.
- [109] New frontiers in the development of vaccines against enterotoxinogenic (ETEC) and enterohaemorrhagic (EHEC) *E. coli* infections. Part I. *Wkly Epidemiol Rec* 1999;74:98-101.
- [110] Ansaruzzaman M, Bhuiyan NA, Begum YA, Kuhn I, Nair GB, Sack DA, et al. Characterization of enterotoxigenic *Escherichia coli* from diarrhoeal patients in Bangladesh using phenotyping and genetic profiling. *J Med Microbiol* 2007;56:217-22.

- [111] Steinsland H, Valentiner-Branth P, Gjessing HK, Aaby P, Molbak K, Sommerfelt H. Protection from natural infections with enterotoxigenic *Escherichia coli*: longitudinal study. *Lancet* 2003;362:286-91.
- [112] Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, et al. Safety and immunogenicity of an enterotoxigenic *Escherichia coli* vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. *Infect Immun* 2007;75:2163-70.
- [113] Svennerholm AM, Tobias J. Vaccines against enterotoxigenic *Escherichia coli*. *Expert Rev Vaccines* 2008;7:795-804.
- [114] Boedeker EC. Vaccines for enterotoxigenic *Escherichia coli*: current status. *Curr Opin Gastroenterol* 2005;21:15-9.
- [115] Svennerholm AM, Holmgren J. Oral vaccines against cholera and enterotoxigenic *Escherichia coli* diarrhea. *Adv Exp Med Biol* 1995;371B:1623-8.
- [116] Jelinek T, Kollaritsch H. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera. *Expert Rev Vaccines* 2008;7:561-7.
- [117] Wiedermann G, Kollaritsch H, Kundi M, Svennerholm AM, Bjare U. Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report). *J Travel Med* 2000;7:27-9.
- [118] Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic *E. coli* diarrhoea of travellers to Guatemala and Mexico. *Vaccine* 2007;25:4392-400.
- [119] Walker RI, Steele D, Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic *E. coli* (ETEC) disease. *Vaccine* 2007;25:2545-66.
- [120] Tobias J, Lebens M, Bolin I, Wiklund G, Svennerholm AM. Construction of non-toxic *Escherichia coli* and *Vibrio cholerae* strains expressing high and immunogenic levels of enterotoxigenic *E. coli* colonization factor I fimbriae. *Vaccine* 2008;26:743-52.
- [121] McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, et al. Comparative safety and immunogenicity of two attenuated enterotoxigenic *Escherichia coli* vaccine strains in healthy adults. *Infect Immun* 2006;74:994-1000.
- [122] Turner AK, Beavis JC, Stephens JC, Greenwood J, Gewert C, Thomas N, et al. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic *Escherichia coli* vaccine strain expressing colonization factor antigen CFA/I. *Infect Immun* 2006;74:1062-71.
- [123] Barry EM, Altboum Z, Losonsky G, Levine MM. Immune responses elicited against multiple enterotoxigenic *Escherichia coli* fimbriae and mutant LT expressed in attenuated *Shigella* vaccine strains. *Vaccine* 2003; 21:333-40.
- [124] Barry EM, Wang J, Wu T, Davis T, Levine MM. Immunogenicity of multivalent *Shigella*-ETEC candidate vaccine strains in a guinea pig model. *Vaccine* 2006; 24:3727-34.
- [125] Khan S, Chatfield S, Stratford R, Bedwell J, Bentley M, Sulsh S, et al. Ability of SPI2 mutant of *S. typhi* to effectively induce antibody responses to the mucosal antigen enterotoxigenic *E. coli* heat labile toxin B subunit after oral delivery to humans. *Vaccine* 2007;25:4175-82.
- [126] Ranallo RT, Fonseka CP, Cassels F, Srinivasan J, Venkatesan MM. Construction and characterization of bivalent *Shigella flexneri* 2a vaccine strains SC608(pCFAI) and

SC608(pCFAI/LTB) that express antigens from enterotoxigenic *Escherichia coli*. *Infect Immun* 2005;73:258-67.

[127] Guarena-Burgueno F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, et al. Safety and immunogenicity of a prototype enterotoxigenic *Escherichia coli* vaccine administered transcutaneously. *Infect Immun* 2002;70:1874-80.

[128] McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic *Escherichia coli* (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. *Vaccine* 2007;25:3684-91.

[129] Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, et al. Use of a patch containing heat-labile toxin from *Escherichia coli* against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. *Lancet* 2008;371:2019-25.

[130] Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. *Vaccine* 2004;22:4385-9.